Article has no nextliveshere tags assigned

Article has no topics tags assigned

Article has no colleges tags assigned

Article has no audiences tags assigned

Article has no units tags assigned

Contacts are empty

These messages will display in edit mode only.

UPI: Promising pancreatic cancer treatment

Media highlights potential new cancer therapy that could be in clinical trials soon

A new multi-drug combination therapy for pancreatic cancer is inching toward clinical trials in humans, according to University of Cincinnati researchers.

The drug compound, called SapC-DOPS, combines chemotherapy with targeted therapy and is capable of killing the cells that cause a number of cancers, including pancreatic cancer, which is notoriously difficult to treat.

"Based on pre-clinical studies, it has the potential to improve pancreatic cancer treatment," Xiaoyang Qi, PhD, a professor of hematology oncology at the University of Cincinnati College of Medicine and member of the UC Cancer Center. Qi is a lead author on the study which was published in the academic journal Molecular Therapy.

Read the full story.

Read the UC news release.

The Cincinnati Enquirer also covered this research.

Featured photo of pancreatic cancer cells courtesy of National Institutes of Health. Credit/Min Yu/Eli and Edythe Broad Center for Regenerative Medicine and Stem Cell Research at USC

Next Lives Here

The University of Cincinnati is classified as a Research 1 institution by the Carnegie Commission and is ranked in the National Science Foundation's Top-35 public research universities. UC's graduate students and faculty investigate problems and innovate solutions with real-world impact. Next Lives Here.